Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Swedish Orphan Biovitrum AB ( (SE:SOBI) ).
Swedish Orphan Biovitrum AB (Sobi) announced the resignation of Helena Saxon from its Board of Directors, effective immediately, as she is set to join the board of another healthcare company. Saxon’s departure marks the end of her significant contributions to Sobi’s strategic development since 2011, as acknowledged by Sobi Chairman David Meek.
The most recent analyst rating on (SE:SOBI) stock is a Buy with a SEK370.00 price target. To see the full list of analyst forecasts on Swedish Orphan Biovitrum AB stock, see the SE:SOBI Stock Forecast page.
More about Swedish Orphan Biovitrum AB
Sobi is a global biopharmaceutical company focused on transforming the lives of people with rare diseases through breakthrough innovations. With around 1,900 employees worldwide, the company operates across Europe, North America, the Middle East, Asia, and Australia, and reported a revenue of SEK 26 billion in 2024. Sobi is publicly traded on Nasdaq Stockholm.
Average Trading Volume: 319,796
Technical Sentiment Signal: Strong Buy
Current Market Cap: SEK105.5B
For detailed information about SOBI stock, go to TipRanks’ Stock Analysis page.